
    
      The healthcare professionals who are vaccinated with this product early after the marketing
      approval of COMIRNATY(participants in the Investigation of Health Status of Recipients
      Vaccinated First conducted by the Science Research Group of the Ministry of Health, Labour
      and Welfare) will be followed for 11 months from the day following 28 days after the final
      vaccination of this product (end date of observation period in Investigation of Health Status
      of Recipients Vaccinated First) to 12 months after the final vaccination of this product,
      information on serious adverse events and COVID-19 observed during the follow-up period will
      be collected, and the long-term safety of this product will be assessed (to be conducted as
      11-month follow-up investigation after completion of Investigation of Health Status of
      Recipients Vaccinated First).
    
  